Calculators

401k Retirement Calculator Mortgage Calculator

New

Student Loan Calculator Auto Loan Calculator

Education

How To Use TipRanks TipRanks Labs Webinar Center Glossary FAQs

About Us

About TipRanks Contact Us Careers Reviews Mobile APP

Working with TipRanks

Enterprise Solutions Top Online Brokers Become an Affiliate

News Trending Portfolio

TOOLS

Top Smart Score Stocks

STOCKS

Best High Yield Dividend Stocks

Dividend Aristocrats

Dividend Stock Comparison

New

Dividend Calculator

Dividend Returns Comparison

Dividend Calendar

Top Analysts

Top Financial Bloggers

Top-Performing Corporate Insiders

Top Hedge Fund Managers

Top Research Firms

Top Individual Investors

News

Portfolio

Personal Finance Center

Mortgages

Loans

Investing & Retirement

Spending & Savings

Calculators

Compound Interest Calculator

Student Loan Calculator

401k Retirement Calculator

Education

About Us

Working with TipRanks

Enterprise Solutions

Top Online Brokers

Become an Affiliate

Novo Nordisk (GB:0QIU)

LSE:0QIU

0QIU

Novo Nordisk

RESEARCH TOOLS

Top Smart Score Stocks

Stock Screener

reports

Novo Nordisk (0QIU) Share Forecast & Price Target

30 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0QIU Analyst Ratings

Moderate Buy

9 Buy

4 Hold

1 Sell

Based on 14 analysts giving stock ratings to

Novo

Nordisk

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0QIU Stock 12 Month Forecast

Average Price Target

kr980.00

▼(-1.97% Downside)

Based on 14 Wall Street analysts offering 12 month price targets for Novo Nordisk in the last 3 months. The average price target is kr980.00 with a high forecast of kr1,200.00 and a low forecast of kr575.00. The average price target represents a -1.97% change from the last price of kr999.71.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"524":"kr524","1201":"kr1,201","693.25":"kr693.3","862.5":"kr862.5","1031.75":"kr1,031.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">kr1.20K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":980,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">kr980.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":575,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">kr575.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[524,693.25,862.5,1031.75,1201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2023","6":"Dec<br/>2023","9":"Mar<br/>2024","12":"Jun<br/>2024","25":"Jun<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,984,1000.6153846153846,1017.2307692307693,1033.8461538461538,1050.4615384615386,1067.076923076923,1083.6923076923076,1100.3076923076924,1116.923076923077,1133.5384615384614,1150.1538461538462,1166.7692307692307,1183.3846153846155,{"y":1200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,984,983.6923076923077,983.3846153846154,983.0769230769231,982.7692307692307,982.4615384615385,982.1538461538462,981.8461538461538,981.5384615384615,981.2307692307693,980.9230769230769,980.6153846153846,980.3076923076923,{"y":980,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,984,952.5384615384615,921.0769230769231,889.6153846153846,858.1538461538462,826.6923076923077,795.2307692307693,763.7692307692307,732.3076923076924,700.8461538461538,669.3846153846155,637.9230769230769,606.4615384615385,{"y":575,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":544.39,"date":1688083200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":532.98,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":525.88,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":640.13,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":640.25,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":676.79,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":693.64,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":719.52,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":782.85,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":844.82,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":863.11,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":843.24,"date":1714694400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":984,"date":1717718400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Targetkr1,200

Average Price Targetkr980.00

Lowest Price Targetkr575.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

xxxxxxxxxxxxxxxxxx

Jefferies

xxxxxxxxxxxxx

Reiterated

07/02/24

xxxxxxxxxxxxxxxxxx

UBS

xxxxxxxxxxxxx

Reiterated

06/28/24

xxxxxxxxxxxxxxxxxx

J.P. Morgan

xxxxxxxxxxxxx

Reiterated

06/27/24

xxxxxxxxxxxxxxxxxx

DNB Markets

xxxxxxxxxxxxx

Reiterated

06/27/24

xxxxxxxxxxxxxxxxxx

Goldman Sachs

xxxxxxxxxxxxx

Reiterated

06/27/24

xxxxxxxxxxxxxxxxxx

Deutsche Numis

xxxxxxxxxxxxx

Reiterated

06/25/24

xxxxxxxxxxxxxxxxxx

Citi

xxxxxxxxxxxxx

Reiterated

06/17/24

xxxxxxxxxxxxxxxxxx

Bank of America Securities

xxxxxxxxxxxxx

Reiterated

06/14/24

xxxxxxxxxxxxxxxxxx

Stifel Nicolaus

xxxxxxxxxxxxx

Reiterated

05/14/24

xxxxxxxxxxxxxxxxxx

Berenberg Bank

xxxxxxxxxxxxx

Reiterated

05/08/24

Emily Field

Barclays

kr1,050

Buy

5.03%

Upside

Reiterated

05/07/24

Elmar Kraus

DZ BANK AG

―

Hold

―

Reiterated

05/03/24

David Evans

Kepler Capital

kr715

Hold

-28.48%

Downside

Reiterated

05/02/24

Analysts Offer Insights on Healthcare Companies: Novo Nordisk (LSE: GB:0QIU), Amplifon S.p.A. (LSE: GB:0N61) and DiaSorin S.p.A. (LSE: GB:0GZX)

Mark Purcell

Morgan Stanley

kr930→kr990

Buy

-0.97%

Downside

Reiterated

04/15/24

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK990 at Morgan StanleyMorgan Stanley analyst Mark Purcell raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK990.00 (from DKK930.00) while maintaining a Overweight rating.

Steve Scala

TD Cowen

kr925→kr1,054

Buy

5.43%

Upside

Reiterated

03/11/24

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK1,054 at TD CowenTD Cowen analyst Steve Scala raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK1,054.00 (from DKK925.00) while maintaining a Outperform rating.

Best Analysts Covering Novo Nordisk

Which Analyst Should I Follow If I Want to Buy GB:0QIU and Sell After:

1 Month

Mark PurcellMorgan Stanley

Success Rate

14/16 ratings generated profit

Average Return

+6.16%

reiterated a buy rating 3 months ago

Copying Mark Purcell's trades and holding each position for 1 Month would result in 87.50% of your transactions generating a profit, with an average return of +6.16% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

3 Months

Emmanuel PapadakisDeutsche Numis

Success Rate

37/46 ratings generated profit

Average Return

+9.76%

reiterated a buy rating 8 days ago

Copying Emmanuel Papadakis's trades and holding each position for 3 Months would result in 80.43% of your transactions generating a profit, with an average return of +9.76% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

1 Year

Emily FieldBarclays

Success Rate

27/27 ratings generated profit

Average Return

+45.19%

reiterated a buy rating 2 months ago

Copying Emily Field's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +45.19% per trade.

2 Years

Emily FieldBarclays

Success Rate

27/27 ratings generated profit

Average Return

+102.34%

reiterated a buy rating 2 months ago

Copying Emily Field's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +102.34% per trade.

dummydummy

Success Rate

0/0 ratings generated profit

Average Return

0.00%

a rating ―

Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.

Premium Content

Find out which analyst has the highest Average Return & Success Rate

Go Premium

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QIU Analyst Recommendation Trends

Rating

Feb 24

Mar 24

Apr 24

May 24

Jun 24

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0QIU has received 21 Buy Ratings, 9 Hold Ratings, and 2 Sell Ratings. 0QIU average Analyst price target in the past 3 months is kr980.00.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0QIU Financial Forecast

0QIU Earnings Forecast

Next quarter’s earnings estimate for 0QIU is kr5.23 with a range of kr4.41 to kr6.22. The previous quarter’s EPS was kr5.68. 0QIU beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 38.00% of the time in the same period. In the last calendar year 0QIU has Outperformed its overall industry.

0QIU Sales Forecast

Next quarter’s sales forecast for 0QIU is kr68.27B with a range of kr64.35B to kr71.05B. The previous quarter’s sales results were kr65.35B. 0QIU beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 42.86% of the time in the same period. In the last calendar year 0QIU has Outperformed its overall industry.

0QIU Stock Forecast FAQ

What is GB:0QIU’s average 12-month price target, according to analysts?

Based on analyst ratings, Novo Nordisk’s 12-month average price target is kr980.00.

What is GB:0QIU’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for GB:0QIU, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Novo Nordisk a Buy, Sell or Hold?

Novo Nordisk has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 4 hold ratings and 1 sell ratings.

What is Novo Nordisk’s share price target?

The average share price target for Novo Nordisk is kr980.00. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is kr1,200.00 ,and the lowest forecast is kr575.00. The average share price target represents -1.97% Decrease from the current price of kr999.708.

What do analysts say about Novo Nordisk?

Novo Nordisk’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of Novo Nordisk?

To buy shares of GB:0QIU, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Novo Nordisk (0QIU) Share Forecast & Price Target

0QIU Analyst Ratings

0QIU Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Novo Nordisk

0QIU Analyst Recommendation Trends

0QIU Financial Forecast

0QIU Earnings Forecast

0QIU Sales Forecast

0QIU Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts